» Articles » PMID: 28557629

Comparative Analysis of 12 Different Kits for Bisulfite Conversion of Circulating Cell-free DNA

Overview
Journal Epigenetics
Specialty Genetics
Date 2017 May 31
PMID 28557629
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Blood circulating cell-free DNA (cfDNA) is becoming popular in the search of promising predictive and prognostic biomarkers. Among these biomarkers, cfDNA methylation markers have especially gained considerable attention. A significant challenge in the utilization of cfDNA methylation markers is the limited amount of cfDNA available for analyses; reportedly, bisulfite conversion (BSC) reduce cfDNA amounts even further. Nevertheless, few efforts have focused on ensuring high cfDNA conversion efficiency and recovery after BSC. To compare cfDNA recovery of different BSC methods, we compared 12 different commercially available BSC kits. We tested whether DNA recovery was affected by the molecular weight and/or quantity of input DNA. We also tested BSC efficiency for each kit. We found that recovery varied for DNA fragments of different lengths: certain kits recovered short fragments better than others, and only 3 kits recovered DNA fragments of <100 bp well. In contrast, DNA input amount did not seem to affect DNA recovery: for quantities spanning between 820 and ∼25,000 genome equivalents per BSC, a linear relation was found between input and recovery amount. Overall, mean recovery ranged between 9 and 32%, with BSC efficiency of 97-99.9%. When plasma cfDNA was used as input for BSC, recovery varied from 22% for the poorest and 66% for the best performing kits, while conversion efficiency ranged from 96 to 100% among different kits. In conclusion, clear performance differences exist between commercially available BSC kits, both in terms of DNA recovery and conversion efficiency. The choice of BSC kit can substantially impact the amount of converted cfDNA available for downstream analysis, which is critical in a cfDNA methylation marker setting.

Citing Articles

Circulating Cell-Free DNA in Metabolic Diseases.

Pollastri A, Kovacs P, Keller M J Endocr Soc. 2025; 9(2):bvaf006.

PMID: 39850787 PMC: 11756337. DOI: 10.1210/jendso/bvaf006.


An appropriate DNA input for bisulfite conversion reveals LINE-1 and Alu hypermethylation in tissues and circulating cell-free DNA from cancers.

Tran T, Pham T, Nguyen T, Hien Do T, Luu P, Nguyen U PLoS One. 2025; 19(12):e0316394.

PMID: 39775734 PMC: 11684646. DOI: 10.1371/journal.pone.0316394.


Evaluation of silica spin‑column and magnetic bead formats for rapid DNA methylation analysis in clinical and point‑of‑care settings.

Zamuner F, Ramos-Lopez A, Garcia-Negron A, Purcell-Wiltz A, Cortes-Ortiz A, Cuevas A Biomed Rep. 2024; 21(2):112.

PMID: 38912171 PMC: 11190640. DOI: 10.3892/br.2024.1800.


The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization.

Bronkhorst A, Holdenrieder S Med Genet. 2024; 35(4):201-235.

PMID: 38835739 PMC: 11006350. DOI: 10.1515/medgen-2023-2065.


DNA methylation markers in esophageal cancer.

Xu Y, Wang Z, Pei B, Wang J, Xue Y, Zhao G Front Genet. 2024; 15:1354195.

PMID: 38774285 PMC: 11106492. DOI: 10.3389/fgene.2024.1354195.


References
1.
Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

2.
Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson W . Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst. 2001; 93(22):1747-52. DOI: 10.1093/jnci/93.22.1747. View

3.
Pedersen S, Symonds E, Baker R, Murray D, McEvoy A, van Doorn S . Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 2015; 15:654. PMC: 4596413. DOI: 10.1186/s12885-015-1674-2. View

4.
Leontiou C, Hadjidaniel M, Mina P, Antoniou P, Ioannides M, Patsalis P . Bisulfite Conversion of DNA: Performance Comparison of Different Kits and Methylation Quantitation of Epigenetic Biomarkers that Have the Potential to Be Used in Non-Invasive Prenatal Testing. PLoS One. 2015; 10(8):e0135058. PMC: 4527772. DOI: 10.1371/journal.pone.0135058. View

5.
Snyder M, Kircher M, Hill A, Daza R, Shendure J . Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016; 164(1-2):57-68. PMC: 4715266. DOI: 10.1016/j.cell.2015.11.050. View